Skin manifestations of COVID‐19 in children : Part 2
Summary The current COVID‐19 pandemic is caused by the SARS‐CoV‐2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS‐CoV‐2 infection in children differ from those in adults, as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID‐19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discussed one of the first and most widespread cutaneous manifestations of COVID‐19, chilblain‐like lesions. In this part of the review, we describe other manifestations, including erythema multiforme, urticaria and Kawasaki disease‐like inflammatory multisystemic syndrome. In Part 3, we discuss the histological findings of COVID‐19 manifestations, and the testing and management of infected children for both COVID‐19 and any other pre‐existing conditions..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Clinical and experimental dermatology - 46(2021), 3, Seite 451-461 |
| Beteiligte Personen: |
Andina, D. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2021 British Association of Dermatologists |
|---|
| Umfang: |
11 |
|---|
| doi: |
10.1111/ced.14482 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY003317846 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY003317846 | ||
| 003 | DE-627 | ||
| 005 | 20230307124950.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230213s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/ced.14482 |2 doi | |
| 028 | 5 | 2 | |a CED_CED14482.xml |
| 035 | |a (DE-627)WLY003317846 | ||
| 035 | |a (WILEY)CED14482 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.93 |2 bkl | ||
| 100 | 1 | |a Andina, D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Skin manifestations of COVID‐19 in children |b Part 2 |
| 264 | 1 | |c 2021 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2021 British Association of Dermatologists | ||
| 520 | |a Summary The current COVID‐19 pandemic is caused by the SARS‐CoV‐2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS‐CoV‐2 infection in children differ from those in adults, as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID‐19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discussed one of the first and most widespread cutaneous manifestations of COVID‐19, chilblain‐like lesions. In this part of the review, we describe other manifestations, including erythema multiforme, urticaria and Kawasaki disease‐like inflammatory multisystemic syndrome. In Part 3, we discuss the histological findings of COVID‐19 manifestations, and the testing and management of infected children for both COVID‐19 and any other pre‐existing conditions. | ||
| 700 | 1 | |a Belloni‐Fortina, A. |4 aut | |
| 700 | 1 | |a Bodemer, C. |4 aut | |
| 700 | 1 | |a Bonifazi, E. |4 aut | |
| 700 | 1 | |a Chiriac, A. |4 aut | |
| 700 | 1 | |a Colmenero, I. |4 aut | |
| 700 | 1 | |a Diociaiuti, A. |4 aut | |
| 700 | 1 | |a El‐Hachem, M. |4 aut | |
| 700 | 1 | |a Fertitta, L. |4 aut | |
| 700 | 1 | |a Gysel, D. |4 aut | |
| 700 | 1 | |a Hernández‐Martín, A. |4 aut | |
| 700 | 1 | |a Hubiche, T. |4 aut | |
| 700 | 1 | |a Luca, C. |4 aut | |
| 700 | 1 | |a Martos‐Cabrera, L. |4 aut | |
| 700 | 1 | |a Maruani, A. |4 aut | |
| 700 | 1 | |a Mazzotta, F. |4 aut | |
| 700 | 1 | |a Akkaya, A. D. |4 aut | |
| 700 | 1 | |a Casals, M. |4 aut | |
| 700 | 1 | |a Ferrando, J. |4 aut | |
| 700 | 1 | |a Grimalt, R. |4 aut | |
| 700 | 1 | |a Grozdev, I. |4 aut | |
| 700 | 1 | |a Kinsler, V. |4 aut | |
| 700 | 1 | |a Morren, M. A. |4 aut | |
| 700 | 1 | |a Munisami, M. |4 aut | |
| 700 | 1 | |a Nanda, A. |4 aut | |
| 700 | 1 | |a Novoa, M. P. |4 aut | |
| 700 | 1 | |a Ott, H. |4 aut | |
| 700 | 1 | |a Pasmans, S. |4 aut | |
| 700 | 1 | |a Salavastru, C. |4 aut | |
| 700 | 1 | |a Zawar, V. |4 aut | |
| 700 | 1 | |a Torrelo, A. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental dermatology |d Kettering : Oxford University Press, 1976 |g 46(2021), 3, Seite 451-461 |w (DE-627)WLY003310450 |w (DE-600)2004506-2 |x 13652230 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2021 |g number:3 |g pages:451-461 |g extent:11 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.93 |q ASE |
| 951 | |a AR | ||
| 952 | |d 46 |j 2021 |e 3 |h 451-461 |g 11 | ||